JPS5936885B2 - 糖尿病治療剤 - Google Patents

糖尿病治療剤

Info

Publication number
JPS5936885B2
JPS5936885B2 JP51074668A JP7466876A JPS5936885B2 JP S5936885 B2 JPS5936885 B2 JP S5936885B2 JP 51074668 A JP51074668 A JP 51074668A JP 7466876 A JP7466876 A JP 7466876A JP S5936885 B2 JPS5936885 B2 JP S5936885B2
Authority
JP
Japan
Prior art keywords
present
compound
diabetes
blood
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51074668A
Other languages
English (en)
Japanese (ja)
Other versions
JPS52156932A (en
Inventor
文義 石川
「あきら」 小笹山
好文 渡辺
雍史 安孫子
欣也 亀田
信悦 小野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP51074668A priority Critical patent/JPS5936885B2/ja
Priority to PH19885A priority patent/PH14847A/en
Priority to FR7719509A priority patent/FR2355501A1/fr
Priority to DE2728589A priority patent/DE2728589C3/de
Priority to US05/809,814 priority patent/US4138491A/en
Publication of JPS52156932A publication Critical patent/JPS52156932A/ja
Publication of JPS5936885B2 publication Critical patent/JPS5936885B2/ja
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP51074668A 1976-06-24 1976-06-24 糖尿病治療剤 Expired JPS5936885B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP51074668A JPS5936885B2 (ja) 1976-06-24 1976-06-24 糖尿病治療剤
PH19885A PH14847A (en) 1976-06-24 1977-06-17 Method for treating diabetes
FR7719509A FR2355501A1 (fr) 1976-06-24 1977-06-24 Nouvelles 2-(ethyl 2,2-disubstitue)-imidazolines, utiles notamment pour le traitement du diabete
DE2728589A DE2728589C3 (de) 1976-06-24 1977-06-24 Verwendung von 2-(2,2-disubstituierten)-Äthylimidazolinen bei der Bekämpfung von Diabetes
US05/809,814 US4138491A (en) 1976-06-24 1977-06-24 Method for treating diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP51074668A JPS5936885B2 (ja) 1976-06-24 1976-06-24 糖尿病治療剤

Publications (2)

Publication Number Publication Date
JPS52156932A JPS52156932A (en) 1977-12-27
JPS5936885B2 true JPS5936885B2 (ja) 1984-09-06

Family

ID=13553832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51074668A Expired JPS5936885B2 (ja) 1976-06-24 1976-06-24 糖尿病治療剤

Country Status (5)

Country Link
US (1) US4138491A (Direct)
JP (1) JPS5936885B2 (Direct)
DE (1) DE2728589C3 (Direct)
FR (1) FR2355501A1 (Direct)
PH (1) PH14847A (Direct)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61194020A (ja) * 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
CA1309027C (en) * 1987-04-27 1992-10-20 Yasumasa Yoshie Antiasthmatic agent containing imidazoline derivative
DK344489D0 (da) * 1989-07-12 1989-07-12 Novo Nordisk As Substituerede 2-imidazoliner og fremstilling og anvendelse deraf
DE4201709A1 (de) * 1992-01-23 1993-07-29 Bayer Ag (alpha)-aryl-(alpha)-hydroxy-ss-imidazolinyl-propionsaeureamide
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
WO2002038559A1 (en) * 2000-11-10 2002-05-16 Novo Nordisk A/S 1,3-diazaheterocyclic compounds and their use as oral hypoglycaemic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH283583A (de) * 1949-02-24 1952-06-15 Spofa Vereinigte Pharma Werke Verfahren zur Herstellung eines neuen Imidazolinabkömmlings.
US2676964A (en) * 1950-06-07 1954-04-27 Schering Corp 3-pyridyl propylamine antihistamine substances
US2604473A (en) * 1950-07-17 1952-07-22 Schering Corp Propylamine type antihistamines

Also Published As

Publication number Publication date
PH14847A (en) 1981-12-16
FR2355501A1 (fr) 1978-01-20
US4138491A (en) 1979-02-06
DE2728589B2 (de) 1978-10-19
DE2728589C3 (de) 1979-06-07
JPS52156932A (en) 1977-12-27
DE2728589A1 (de) 1978-01-05
FR2355501B1 (Direct) 1980-05-09

Similar Documents

Publication Publication Date Title
JP4689838B2 (ja) Ｎ−［２−ヒドロキシ−３−（１−ピペリジニル）プロポキシ］ピリジン−１−オキシド−３−カルボキシイミドイルクロライド及びそのインスリン抵抗性の治療における使用
JP2004503585A (ja) 薬剤混合物
JP3852621B2 (ja) 血管内皮細胞機能改善剤
JPH0531523B2 (Direct)
RU2145220C1 (ru) Способ замедления прогрессирования атеросклероза коронарных артерий с помощью правастатина
ROMHILT et al. Evaluation of bretylium tosylate for the treatment of premature ventricular contractions
JPS5936885B2 (ja) 糖尿病治療剤
KR0180248B1 (ko) 항당뇨병약품
US3541218A (en) Omicron-fluorobenzylaminoguanidine for diabetes
EP0928191B1 (en) Pharmaceutical compositions comprising s-alkylisothiouronium derivatives
SU1598870A3 (ru) Способ получени производных 1,4-дигидропиридина
DE69200365T2 (de) Pharmazeutische Zusammensetzung zur Verbesserung von Dysuria.
JP2889663B2 (ja) 真性糖尿病の処置法
JP2835547B2 (ja) 糖尿病治療剤
US3852454A (en) Treatment of rheumatoid arthritis
DE3781339T2 (de) Therapeutisches mittel fuer gastritis.
DE3410218A1 (de) Tergurid als antihypertensivum
US20250041315A1 (en) Levonorgestrel butanoate formulation and methods relating thereto
DE2951669C2 (de) Arzneimittel
US4151281A (en) Medicinal preparation for the treatment of collagenoses of a rheumatoid nature
Depeyster et al. Clinical response of spontaneous hypoglycemia to dietary and drug therapy
DE60214185T2 (de) Pharmazeutische kombination mit (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenylethoxy) phenyl propansäure oder 3-4-2-(4-tert.-butoxycarbonylaminophenyl) ethoxyphenyl-(s)-2-ethoxypropansäure und einem biguanid-arzneimittel
JP3007097B2 (ja) 睡眠薬組成物
Houghton THE PHARMACOLOGY OF THE SUPRARENAL GLAND AND A METHOD OF ASSAYING ITS PRODUCTS.
WO1991000091A1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica